Citadel Advisors’s Artelo Biosciences ARTL Stock Holding History

Citadel Advisors’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,261	Closed	-$19.9K	–	12444
2025 Q1	$19.9K	Buy	+1,261	New	+$25.3K	﹤0.01%	13146
2022 Q1	–	Sell	-291	Closed	-$41K	–	13526
2021 Q4	$41K	Buy	291 +188	+183%	+$37.1K	﹤0.01%	13352
2021 Q3	$22K	Sell	103 -172	-63%	-$43.7K	﹤0.01%	13632
2021 Q2	$88K	Sell	275 -395	-59%	-$135K	﹤0.01%	13016
2021 Q1	$295K	Buy	+670	New	+$286K	﹤0.01%	10893

Other funds holding ARTL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's ARTL Position: Q2 2025 in Review

Citadel Advisors sold out of Artelo Biosciences (ARTL) in Q2 2025, closing a stake of 1,261 shares — an estimated $19.9K sold.

Citadel Advisors first reported a position in ARTL in Q1 2021 and held it in 5 quarters. The position peaked at $295K in Q1 2021. 6 funds tracked by Wall St. Rank hold ARTL as of Q2 2025.

Citadel Advisors reported no remaining Artelo Biosciences position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 1,261 Artelo Biosciences shares in Q2 2025, an estimated $19.9K.
Citadel Advisors first reported a position in Artelo Biosciences in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Artelo Biosciences position peaked at $295K in Q1 2021.
6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.